Shiha, Gamal; Esmat, Gamal; Hassany, Mohamed; Soliman, Reham; Elbasiony, Mohamed; Fouad, Rabab; Elsharkawy, Aisha; Hammad, Radi; Abdel-Razek, Wael; Zakareya, Talaat; Kersey, Kathryn; Massetto, Benedetta; Osinusi, Anu; Lu, Sophia; Brainard, Diana M.; McHutchison, John G.; Waked, Imam; Doss, Wah published the artcile< Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt>, HPLC of Formula: 58-97-9, the main research area is hepatitis c virus infection ledipasvir sofosbuvir ribavirin safety Egypt; chronic hepatitis; cirrhosis; genotype.
We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 wk in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. Design In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 wk of ledipasvir/sofosbuvir±ribavirin. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 wk of ledipasvir/sofosbuvir alone and with ribavirin, resp., and 98% for those receiving 12 wk of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 wk of ledipasvir/ sofosbuvir and 100% for those receiving 12 wk of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin. A mong non-cirrhotic treatment-naive patients with HCV genotype 4, 8 wk of ledipasvir/ sofosbuvir±ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir±ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir.
Gut published new progress about Anemia. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem